157 related articles for article (PubMed ID: 25756405)
21. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
Higashi M; Kajiyama H; Shibata K; Mizuno M; Mizuno K; Hosono S; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
Gynecol Oncol; 2011 Dec; 123(3):474-8. PubMed ID: 21955484
[TBL] [Abstract][Full Text] [Related]
22. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
23. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas.
Nishimura S; Tsuda H; Ito K; Takano M; Terai Y; Jobo T; Kigawa J; Sugiyama T; Yaegashi N; Aoki D
Int J Gynecol Cancer; 2010 Feb; 20(2):220-6. PubMed ID: 20134266
[TBL] [Abstract][Full Text] [Related]
26. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
[TBL] [Abstract][Full Text] [Related]
27. Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer.
Inokuchi M; Murase H; Otsuki S; Kawano T; Kojima K
World J Surg Oncol; 2017 Jan; 15(1):2. PubMed ID: 28056982
[TBL] [Abstract][Full Text] [Related]
28. Expression of CXCR4 indicates poor prognosis in patients with clear cell carcinoma of the ovary.
Sekiya R; Kajiyama H; Sakai K; Umezu T; Mizuno M; Shibata K; Yamamoto E; Fujiwara S; Nagasaka T; Kikkawa F
Hum Pathol; 2012 Jun; 43(6):904-10. PubMed ID: 22169254
[TBL] [Abstract][Full Text] [Related]
29. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
Rosen DG; Yang G; Cai KQ; Bast RC; Gershenson DM; Silva EG; Liu J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):632-7. PubMed ID: 15701850
[TBL] [Abstract][Full Text] [Related]
30. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
Oe S; Hasegawa K; Nagase S; Kato R; Torii Y; Udagawa Y
Int J Gynecol Pathol; 2010 Sep; 29(5):405-10. PubMed ID: 20736762
[TBL] [Abstract][Full Text] [Related]
31. Twist expression predicts poor clinical outcome of patients with clear cell carcinoma of the ovary.
Kajiyama H; Hosono S; Terauchi M; Shibata K; Ino K; Yamamoto E; Nomura S; Nawa A; Kikkawa F
Oncology; 2006; 71(5-6):394-401. PubMed ID: 17690559
[TBL] [Abstract][Full Text] [Related]
32. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer.
Sun S; Jiang Y; Zhang G; Song H; Zhang X; Zhang Y; Liang X; Sun Q; Pang D
J Surg Oncol; 2012 Jun; 105(8):773-9. PubMed ID: 22006548
[TBL] [Abstract][Full Text] [Related]
33. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
34. Annexin IV is differentially expressed in clear cell carcinoma of the ovary.
Miao Y; Cai B; Liu L; Yang Y; Wan X
Int J Gynecol Cancer; 2009 Dec; 19(9):1545-9. PubMed ID: 19955935
[TBL] [Abstract][Full Text] [Related]
35. Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion.
Wu J; Han W; Yang W; Liu H; Li C; Guo L; Jin Y; Zhang R; Chen H
J Cancer Res Ther; 2018 Jun; 14(Supplement):S347-S353. PubMed ID: 29970688
[TBL] [Abstract][Full Text] [Related]
36. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.
Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1353-7. PubMed ID: 20009889
[TBL] [Abstract][Full Text] [Related]
37. Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.
Choi JY; Han HH; Kim YT; Lee JH; Kim BG; Kang S; Cho NH
Yonsei Med J; 2017 Jan; 58(1):59-66. PubMed ID: 27873496
[TBL] [Abstract][Full Text] [Related]
38. X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.
Miyamoto M; Takano M; Iwaya K; Shinomiya N; Kato M; Aoyama T; Sasaki N; Goto T; Suzuki A; Hitrata J; Furuya K
Br J Cancer; 2014 Jun; 110(12):2881-6. PubMed ID: 24853184
[TBL] [Abstract][Full Text] [Related]
39. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
[TBL] [Abstract][Full Text] [Related]
40. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]